Vanguard Capital Management
JSPR icon

Vanguard Capital Management’s Jasper Therapeutics JSPR Stock Holding History

Vanguard Capital Management’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$493K Sell
1,172,021
-576
-0% -$431 ﹤0.01% 3713
2026
Q1 		$1.03M Buy
+1,172,597
New +$1.63M ﹤0.01% 3547

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management's JSPR Position: Q2 2026 in Review

Vanguard Capital Management reduced its Jasper Therapeutics (JSPR) stake by 0.05% in Q2 2026, selling an estimated $431 and leaving 1,172,021 shares worth $493K. The position accounts for ﹤0.01% of the portfolio, ranked #3713.

Vanguard Capital Management first reported a position in JSPR in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.03M in Q1 2026. 41 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

  • Vanguard Capital Management held 1,172,021 shares of Jasper Therapeutics worth $493K as of Q2 2026.
  • Vanguard Capital Management sold 576 Jasper Therapeutics shares in Q2 2026, an estimated $431.
  • Jasper Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3713 holding.
  • Vanguard Capital Management first reported a position in Jasper Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Jasper Therapeutics position peaked at $1.03M in Q1 2026.
  • 41 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.